LaserGen
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
N/A | $5.0m | Series A | |
$80.0m | Series B | ||
$105m Valuation: $105m | Acquisition | ||
Total Funding | AUD131m |
Related Content
Recent News about LaserGen
EditLasergen, now part of Agilent, specializes in developing and building innovative life science instrumentation. The company serves clinical diagnostics labs and life science research facilities, offering a range of products including the K6460 LC MS system, which is a fully validated and easily implemented solution for clinical diagnostics. Lasergen operates in the life sciences market, focusing on enhancing lab productivity and providing comprehensive solutions for glycan analysis and cell analysis platforms. The business model revolves around selling advanced scientific instruments and providing technical expertise through webinars and other educational resources. Revenue is generated through the sale of these high-performance instruments and related services.
Keywords: life science instrumentation, clinical diagnostics, research labs, LC MS system, glycan analysis, cell analysis, lab productivity, technical expertise, scientific instruments, Agilent.